{"id":"ozagrel","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OZAGREL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:28:21.743422+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:28:27.692329+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OZAGREL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:28:28.049617+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL542549/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:28.755403+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:36:28.954Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:30.405584+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT00200356","phase":"PHASE4","title":"Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-08","conditions":"Cerebral Infarction","enrollment":401}],"_emaApprovals":[],"_faersSignals":[{"count":32,"reaction":"CEREBRAL INFARCTION"},{"count":8,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"},{"count":8,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":8,"reaction":"PNEUMONIA ASPIRATION"},{"count":8,"reaction":"RENAL IMPAIRMENT"},{"count":7,"reaction":"HAEMORRHAGIC CEREBRAL INFARCTION"},{"count":7,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":7,"reaction":"MUSCLE HAEMORRHAGE"},{"count":7,"reaction":"PLATELET COUNT DECREASED"},{"count":6,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"}],"crossReferences":{"chemblId":"CHEMBL542549"},"_approvalHistory":[],"publicationCount":225,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"OZAGREL","genericName":"OZAGREL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1988","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:30.405584+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}